| P2093 | author name string | Babasaheb Sonawane | |
| | Gary Ginsberg | |
| | Dale Hattis | |
| | Patricia Neafsey | |
| P2860 | cites work | Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase | Q28289652 |
| | A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6 | Q28328574 |
| | Biotransformation of Post-Clozapine Antipsychotics | Q30040355 |
| | Dextromethorphan O-demethylation polymorphism in an African-American population | Q33178911 |
| | Drug metabolism polymorphisms as modulators of cancer susceptibility. | Q33650419 |
| | Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans | Q33899650 |
| | Polymorphic hydroxylation of Debrisoquine in man. | Q34057031 |
| | Guidelines for human gene nomenclature. An international system for human gene nomenclature (ISGN, 1987). | Q34181303 |
| | Metabolic genetic polymorphisms and susceptibility to lung cancer | Q34233929 |
| | Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin | Q34241704 |
| | The changing cigarette, 1950-1995. | Q34423399 |
| | Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians | Q34434115 |
| | Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes | Q34477526 |
| | Non-linear pharmacokinetics of MDMA ('ecstasy') in humans | Q34507084 |
| | Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans | Q34546846 |
| | CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine | Q34564302 |
| | Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects | Q34568712 |
| | CYP1A2 activity as a risk factor for bladder cancer | Q34654395 |
| | Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events. | Q54579437 |
| | The association of CYP2D6 *10 polymorphism with breast cancer risk and clinico-pathologic characteristics in Chinese women. | Q54590839 |
| | Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. | Q54593894 |
| | CYP2D6 genotype and phenotype in Amerindians of Tepehuano origin and Mestizos of Durango, Mexico. | Q54605695 |
| | Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population | Q56832337 |
| | CYP2D6 polymorphism in Parkinson's disease: The Rotterdam study | Q57782077 |
| | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine as a Substrate of Cytochrome P450 2D6: Allosteric Effects of NADPH−Cytochrome P450 Reductase† | Q58573225 |
| | Metabolic oxidation phenotypes as markers for susceptibility to lung cancer | Q59082319 |
| | Comparison of normal and asthmatic circadian rhythms in peak expiratory flow rate | Q34718697 |
| | Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. | Q34836887 |
| | Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry | Q35584152 |
| | Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication | Q35594563 |
| | Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity | Q35922156 |
| | Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes | Q36055234 |
| | Neurobiology of cocaine abuse | Q36208834 |
| | Debrisoquine metabolism and genetic predisposition to lung cancer | Q36467770 |
| | The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants | Q36510896 |
| | Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions | Q36851934 |
| | Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients | Q38877282 |
| | A silent mutation (2939G>A, exon 6; CYP2D6*59) leading to impaired expression and function of CYP2D6. | Q40227658 |
| | Sequence-based CYP2D6 genotyping in the Korean population | Q40315510 |
| | Evidence for the activation of organophosphate pesticides by cytochromes P450 3A4 and 2D6 in human liver microsomes | Q40853873 |
| | Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer | Q40992263 |
| | Recent studies on mechanisms of bioactivation and detoxification of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific lung carcinogen | Q41019911 |
| | Kinetic analysis of the activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by heterologously expressed human P450 enzymes and the effect of P450-specific chemical inhibitors on this activation in human liver microsomes | Q41172095 |
| | Lung cancer and the debrisoquine metabolic phenotype | Q41235407 |
| | No association between schizophrenia and polymorphisms within the genes for debrisoquine 4-hydroxylase (CYP2D6) and the dopamine transporter (DAT). | Q41652979 |
| | Dopamine formation from tyramine by CYP2D6. | Q42539834 |
| | Dextromethorphan and ecstasy pills | Q43539057 |
| | Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. | Q43707233 |
| | Genetic polymorphism of CYP2D6 and lung cancer risk in African-Americans and Caucasians in Los Angeles County | Q43762018 |
| | Oxidation of phenethylamine derivatives by cytochrome P450 2D6: the issue of substrate protonation in binding and catalysis | Q43803166 |
| | Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes | Q44524934 |
| | Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity | Q44850319 |
| | Increased liability of tramadol-warfarin interaction in individuals with mutations in the cytochrome P450 2D6 gene | Q44936825 |
| | Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa | Q45056884 |
| | Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution. | Q45279397 |
| | Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs | Q46146192 |
| | Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population | Q46154415 |
| | The frequency of candidate alleles for CYP2D6 genotyping in the Japanese population with an additional respect to the -1584C to G substitution | Q46459037 |
| | Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles | Q46489932 |
| | Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe | Q46504068 |
| | Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study | Q46551877 |
| | CYP2D6 genetic polymorphism in South Indian populations | Q46706279 |
| | Metoprolol and debrisoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation | Q46770380 |
| | CYP2D6*36 gene arrangements within the cyp2d6 locus: association of CYP2D6*36 with poor metabolizer status | Q46895596 |
| | Nicotine metabolism defect reduces smoking | Q47877657 |
| | CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease | Q48019775 |
| | Sequence-based analysis of the CYP2D6*36-CYP2D6*10 tandem-type arrangement, a major CYP2D6*10 haplotype in the Japanese population | Q48085914 |
| | Effect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population | Q48664314 |
| | Nomenclature for the description of human sequence variations | Q48738393 |
| | Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization. | Q48807549 |
| | CYP2D6 gene test in psychiatric patients and healthy volunteers. | Q51920384 |
| | CYP2D6 ultrarapid metabolizer genotype as a potential modifier of smoking behaviour. | Q52278234 |
| | The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis. | Q52892865 |
| | A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation | Q53495214 |
| | A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. | Q53798929 |
| P433 | issue | 5-6 | |
| P921 | main subject | population distribution | Q110583070 |
| P304 | page(s) | 334-361 | |
| P577 | publication date | 2009-01-01 | |
| P1433 | published in | Journal of Toxicology and Environmental Health Part B: Critical Reviews | Q15724534 |
| P1476 | title | Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity | |
| P478 | volume | 12 | |